Skip to content
Physician-backed infrastructure for aesthetic & wellness practicesSupport 9 AM–5 PM EST ·(888) 996-6173 ·info@medgrid.com
MedGrid

FDA's Compounding Calendar: Where GLP-1s and Peptides Stand and What Is Still Pending Into 2027

FDA's compounding picture for GLP-1s and peptides is a set of open items, not a settled rule. Here is what is decided, what is under review and what has no date, as of October 25, 2026.

Category
Compliance
Published
October 25, 2026
Read time
4 minutes

Key Highlights

  • FDA proposed in May 2026 not to include semaglutide, tirzepatide or liraglutide on the 503B bulks list, the comment period closed July 30, 2026 and no final notice date is set.
  • FDA's GLP-1 page says retatrutide and cagrilintide cannot be used in compounding and that semaglutide salts should not be, and FDA has sent waves of warning letters focused on marketing claims.
  • HHS released a draft enforcement discretion policy for six peptides on October 28, 2026, published October 30 with a two-week comment period, which is not approval and not a listing on the bulks list.
  • A second advisory committee meeting on five more peptides is expected before the end of February 2027 with no date set, and formally adding substances to the 503A bulks list takes rulemaking that may not finish before 2028.

Clinics that offer compounded GLP-1s or peptides are watching several FDA tracks at once, and each has a different status. This article lists them in one place with the source status of each, as of October 25, 2026.

GLP-1s: Semaglutide and Tirzepatide

Tirzepatide is not on FDA's drug shortage list, and semaglutide came off the list in February 2025, according to a secondary source. FDA's May 1, 2026 notice on the 503B bulks list proposes not to include semaglutide, tirzepatide or liraglutide. The comment deadline was extended to July 30, 2026, FDA said it may finalize the proposal without change and it will respond to a semaglutide citizen petition at the same time. That notice concerns 503B outsourcing facilities and does not analyze 503A compounding by individual pharmacies, which is a separate pathway. No final notice date is set.

What FDA Says About Specific Products

  • Retatrutide and cagrilintide: FDA's GLP-1 page, current as of October 1, 2026, says they cannot be used in compounding.
  • Semaglutide salt forms: the same page says semaglutide sodium and acetate salts should not be used in compounding.
  • Import controls: a green-list import alert is in place.
  • Adverse event reports: as of May 31, 2026, FDA had received 990 reports for compounded semaglutide and more than 730 for tirzepatide.
  • Warning letters: reported waves of warning letters in September 2025, early 2026 and June 2026 focused on claims that a compounded product is the same as an approved drug and on misleading marketing, plus a September 2026 letter on GLP-1 products with added vitamins.

Peptides: The Interim Access Policy

HHS released a draft Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances on October 28, 2026, after it was received for White House review on October 14. The Federal Register notice publishes October 30, with written comments due two weeks later, about November 13. It says HHS does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding with a peptide in the policy's Appendix A. News reports say that covers BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500, with conditions such as an FDA-registered manufacturer and a certificate of analysis for each batch. It is enforcement discretion, which is not approval, not a bulks list listing and not binding, and HHS may revisit it. Our separate article covers it in detail.

Peptides: The Advisory Committee Track

  • April 15, 2026: FDA removed 12 peptides from Category 2 of its interim policy, which did not make any of them eligible for compounding.
  • June 29, 2026: FDA staff briefing documents recommended against adding any of the seven peptides under review.
  • July 23 and 24, 2026: the advisory committee voted to recommend adding BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax to the 503A bulks list, and voted against emideltide.
  • August and September 2026: FDA sent warning letters to online peptide vendors, and illnesses in at least four states were linked to compounded glutathione injections.
  • Before the end of February 2027: a second meeting is expected on GHK-Cu, LL-37, Dihexa, Melanotan II and PEG-MGF, with no date set.

What Is Not Decided

FDA is not bound by the committee's vote, and formally adding a substance to the 503A bulks list requires rulemaking, which one law-firm alert says may not finish until 2028. Federal funding is also set to expire December 11, 2026 under the current continuing resolution, which could affect timing. We found no dated FDA GLP-1 deadline in 2027.

What a Clinic Should Do

  • Hold the menu to what is authorized today: not to what a committee recommended or a policy might allow.
  • Ask the pharmacy in writing: what it is permitted to compound now, and what it is relying on.
  • Review marketing: for sameness claims and for evidence claims that are stronger than the evidence.
  • Keep a watch list: of substances paused or pending, with who decided and why.
  • Plan the patient message: so patients hear the same plain thing from every staff member.

Where MedGrid Fits

MedGrid keeps a clinic's GLP-1 and peptide menu tied to the medical director's protocols and the pharmacy's actual status, so a change in FDA's position is handled in the next protocol review and not discovered later.

Frequently Asked Questions

  • Is compounded semaglutide still allowed?: FDA's position is that it removed semaglutide from the shortage list and warns against copies, salt forms and misleading claims. 503A compounding for an individual patient is a separate question that depends on the pharmacy, the prescriber and state law.
  • Will FDA add BPC-157 to the bulks list?: Unknown. The advisory committee recommended it, FDA staff did not, and adding a substance requires rulemaking.
  • What is the interim access policy?: A reported FDA enforcement discretion policy for certain compounded peptides, under White House review since October 14, 2026, with its text not public.
  • When is the next peptide advisory meeting?: Expected before the end of February 2027, with no date set.
  • Does the 503B proposal ban compounded GLP-1s?: No. It concerns the 503B bulks list and does not analyze 503A compounding.

This article is general educational information, not legal advice. The dates and rules described were accurate as of October 25, 2026 and several are still pending or projected, so confirm current status with your medical director and health care regulatory counsel before making a decision.

MedGrid MSO provides management services to independently owned practices; it does not practise medicine and does not direct clinical decisions. Requirements vary by state and by service, and change over time — nothing on this page is legal or medical advice. Talk to us or your own counsel before making a structural decision for your clinic.

Get in Touch

Questions About Your State?